[Refractory psoriasis treatment with etanercept].

Background And Objectives: Etanercept is a dimeric fusion protein that binds to tumor necrosis factor and blocks inflammatory response. The purpose of this study was to assess the effects of etanercept and its maintenance in patients with severe and refractory psoriasis.

Patients And Method: Twenty two patients with severe and refractory psoriasis in an open-label clinical trial were studied.

[Prognostic factors of localized malignant melanoma: study of 639 patients].

Background And Objective: Several clinical and histological prognostic factors have been identified in localized melanoma. However, further studies with better defined and more reproducible histological parameters are needed. Our aim was to identify the prognostic factors for survival in cutaneous melanoma in the Spanish population.

[Treatment of severe refractory psoriasis with infliximab].

Background And Objective: Infliximab is a chimeric monoclonal antibody that binds to tumor necrosis factor alpha and blocks the inflammatory response. The purpose of this study was to assess the effects of infliximab in patients with severe and refractory psoriasis.

Patients And Method: Eleven patients with severe and refractory psoriasis were included in an open-label clinical trial.